Negative Patient Care Perceptions Linked to Increased Number of Pre-diagnostic Consultations
the Cancer Therapy Advisor take:
There is a negative association between multiple pre-referral consultations with a general practitioner and the patient experience of subsequent cancer care, according to an article published online in the European Journal of Cancer Care.
The study included data from 73,462 respondents to two English Cancer Patient Experience Surveys. The authors evaluated the likelihood of patients reporting negative experiences of subsequent care after three or more (3+) pre-referral consultations compared to one or two consultations.
Results showed a strong correlation (P<0.01 for all) between patients with 3+ pre-referral consultations and perceived worse care experiences (for 10/12 questions), compared to those with 1-2 consultations ranging from 1.10 to 1.68 (95% CI: 1.03, 1.17 vs. 1.60-1.77, respectively).
In other words, patients with 3+ consultations had a +1.8% to +10.6% greater percentage of reporting a negative subsequent care experience than those with 1-2 visits.
The associations were reported to be stronger when related to primary care as opposed to hospital care, and for evaluation than report items.
Furthermore, a “dose-response” relationship was found after considering 1, 2, 3-4, and 5+ pre-referral consultations separately.
There is a negative association between multiple pre-referral consultations with a general practitioner and the patient experience.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer